Novartis Ag

Unversität Zürich

University of Zürich

Novartis Pharma Gmbh

Mauro Zurini

Martin E Schwab

Carmen Barske

Anis Khusro Mir

Alessandra Vitaliti

Thomas Oertle

Lisa Schnell

Thomas Huber

Mara Fornaro

This invention is in the field of IGF-1 modifications. In particular, it relates to modified IGF-polypeptides and modified IGF-1 precursor polypeptides wherein the cleavage of E-peptide is prevented. The invention also relates to the use of such polypeptides for treating muscle diseases and disorders.

Stabilized insulin-like growth factor polypeptides

This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant, 1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.

Antibody (11C7) anti Nogo-A and its pharmaceutical use

This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant &#x3c;1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.

Antibody (11C7) anti nogo a and its pharmaceutical use

Growing community of inventors

Binningen, Switzerland

Mauro Zurini